Crispr Therapeutics Ag (CRSP) Stock Price & Analysis

Crispr Therapeutics Ag (CRSP) rose 0.00% to USD 46.54 as of July 25, 2026 at 01:45 UTC, according to Nexqual real-time market data.

CRSP last closed at USD 46.54; the session ranged USD 45.92–48.07 on volume of 1,323,665 shares. Market capitalization is —, with a 52-week range of USD 44.12–78.48 (NGM). Source: Nexqual, July 25, 2026 at 01:45 UTC.

Key Statistics (as of July 25, 2026 at 01:45 UTC)

Technical Analysis (CRSP)

Nexqual's technical model rates CRSP "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:45 UTC.

From Crispr Therapeutics Ag's Latest SEC 10-K Filing (filed 2026-02-12)

Key Strengths & Strategy (as disclosed to the SEC)

• For example, we have developed a proprietary, next-generation, site-specific gene correction platform called SyNTase editing.
• To turn this promise into reality, we have built a broad and diversified pipeline of product candidates leveraging gene-based technologies, including CRISPR/Cas9 gene editing technology. 4   Our Pipeline The following table summarizes the status of our product development pipeline: Hemoglobinopathies Hemoglobinopathies are a diverse group of inherited blood disorders that result from variations in the synthesis or structure of hemoglobin.
• We continue to innovate on our platform to develop next-generation technologies that can enable new therapies.
• We believe that our innovative research, translational expertise, and clinical development experience, position us as a leader in the development of CRISPR-based therapeutics and may enable us to create an entirely new class of highly effective and potentially curative therapies for patients with both common and rare diseases for whom current biopharmaceutical approaches have had limited success.

Partnerships

• CASGEVY is the first therapy to emerge from our strategic partnership with Vertex and is being advanced under a joint development and commercialization agreement between us and Vertex and certain of its affiliates.
• We are also pursuing additional delivery technologies, including LNPs, for delivery to tissues beyond the liver, including hematopoietic stem cells and T cells. siRNA-based Programs Our siRNA-based portfolio includes clinical-stage programs in cardiovascular and thromboembolic diseases, developed in collaboration with Sirius Therapeutics and certain of its affiliates, or Sirius.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:45 UTC. This page is informational and not investment advice.